{rfName}
Mu

Indexed in

License and Use

Icono OpenAccess

Citations

23

Altmetrics

Analysis of institutional authors

Ballbe, MontseAuthorFernandez, EAuthor

Share

March 15, 2019
Publications
>
Article
Sí

Multimodal treatment for smoking cessation with varenicline in alcoholic, methadone-maintained, and psychotic patients: A one-year follow-up

Publicated to: Tobacco Induced Diseases. 16 (58): 58- - 2018-12-01 16(58), DOI: 10.18332/tid/99541

Authors: Raich, A; Pinet, C; Ballbè, M; Mondon, S; Tejedor, R; Arnau, A; Fernàndez, E; Cano, M; Carcolé, B; Fernández, T; Martínez, A; Nieva, G; Roig, P; Serra, I; Serrano, J

Affiliations

Addiction Unit, Mental Health Department, Hospital de Sant Pau, Barcelona, Spain. - Author
Addictions Unit, Psychiatry Department, Neurosciences Institute, Hospital Clinic, IDIBAPS, Barcelona, Spain. - Author
Althaia Xarxa Assistencial Univ Manresa, Dept Mental Hlth, Grp Res SAMIS, Barcelona, Spain - Author
Althaia Xarxa Assistencial Univ Manresa, Res Dept, Barcelona, Spain - Author
Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, Barcelona, Spain. - Author
Group of Research SAMIS, Mental Health Department, Althaia Xarxa Assistencial Universitària de Manresa, Barcelona, Spain. - Author
Hosp Clin Barcelona, IDIBAPS, Neurosci Inst, Addict Unit,Psychiat Dept, Barcelona, Spain - Author
Hosp Sant Pau, Dept Mental Hlth, Addict Unit, Barcelona, Spain - Author
IDIBELL, Inst Catala Oncol, Tobacco Control Unit, Barcelona, Spain - Author
Research Department, Althaia Xarxa Assistencial Universitària de Manresa, Barcelona, Spain. - Author
Tobacco Control Unit, Institut Català d'Oncologia, IDIBELL, Barcelona, Spain. - Author
Univ Barcelona, Sch Med, Dept Clin Sci, Barcelona, Spain - Author
See more

Abstract

Numerous studies have evaluated the efficacy and safety of varenicline for smoking cessation in smokers in the general population and, to a lesser extent, among the psychiatric population. However, few studies have evaluated varenicline in patients with other addictions. The present study was conducted to assess outcomes of a multimodal treatment for smoking cessation intervention with varenicline in a sample of alcohol and substance use disorders and patients with psychotic disorders.This was a prospective, multicenter study. The patient sample comprised alcoholics in remission, methadone-maintained patients, and patients with psychotic disorders, all of whom wanted to stop smoking. All participants received multimodal treatment for smoking cessation therapy (psychological therapy plus varenicline). Smoking abstinence and changes in the psychopathological state of patients were assessed at predefined time points during a 12-month follow-up. The probability of tobacco abstinence after one year of treatment was computed using Kaplan-Meier life tables.The probability of abstinence at one year was 0.225 (95% CI: 0.1430-0.319). By group, the probabilities were as follows: patients with psychotic disorders 0.254 (95% CI: 0.118-0.415); alcoholics 0.237 (95% CI: 0.098-0.409); and methadone-maintained patients 0.177 (95% CI: 0.065-0.335). Patients with previous quit attempts had a higher probability of achieving abstinence at one year (p<0.01).The results of this study support the use of multimodal treatment with varenicline in patients with alcohol addiction in remission, patients on methadone maintenance, and patients with stable psychotic disorders. Previous smoking cessation attempts were predictive of smoking cessation success in these patients.

Keywords

addicted patientsmultimodal treatmentpsychoticAddicted patientsMultimodal treatmentPsychoticVarenicline

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Tobacco Induced Diseases due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2018, it was in position 67/164, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Public, Environmental & Occupational Health. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Health (Social Science).

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-12-15:

  • WoS: 8
  • Scopus: 5
  • Europe PMC: 7

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-12-15:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 36.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 37 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 3.

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: http://hdl.handle.net/2445/135760